Announcements Trials

Browse Landscape

Phase

Status

Unknown 3 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Stomach Neoplasms 6 Carcinoma, Non-Small-Cell Lung 4 Squamous Cell Carcinoma of Head and Neck 3 Esophageal Squamous Cell Carcinoma 3 Esophageal Neoplasms 3 Carcinoma, Hepatocellular 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Triple Negative Breast Neoplasms 2 Recurrence 2 Neoplasm Metastasis 2 Nasopharyngeal Carcinoma 2 Cholangiocarcinoma 2 Biliary Tract Neoplasms 2 Advanced Gastric Cancer 2 Thoracic Neoplasms 1 Solid Tumor 1 Small Cell Lung Carcinoma 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Osteosarcoma 1 Neoplasms by Site 1 Mouth Neoplasms 1 Lung Neoplasms 1 Lung Diseases 1 Liver Diseases 1 Hodgkin Disease 1 Hematologic Neoplasms 1 Gestational Trophoblastic Disease 1 Gastrointestinal Neoplasms 1

Interventions

Carboplatin 49 Etoposide 46 Cisplatin 42 Topotecan 39 Irinotecan 21 Paclitaxel 20 Nivolumab 15 pembrolizumab 13 Gemcitabine 13 atezolizumab 11 Ipilimumab 11 durvalumab 9 Radiotherapy 9 Doxorubicin 7 Bevacizumab 7 rovalpituzumab tesirine 6 etoposide phosphate 6 amrubicin 6 Psychiatric Rehabilitation 6 PM 01183 6 Docetaxel 6 Counseling 6 trilaciclib 5 Temozolomide 5 Sunitinib 5 Platinum 5 Imatinib Mesylate 5 Cyclophosphamide 5 Bortezomib 5 130-nm albumin-bound paclitaxel 5

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Completed × Small Cell Lung Carcinoma × camrelizumab × Clear all

NCT03417895 2024-08-07

PASSION

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed

59 enrolled 17 charts

Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡